Rena Therapeutics

About:

Rena Therapeutics is a creation of new nucleic acid drugs realized by third-platform technology

Website: https://www.renatherapeutics.com/

Top Investors: Innovation Network Corporation of Japan, DBJ Capital, KSP, Nippon Shokubai

Description:

In the pharmaceutical market, attention has been focused on nucleic acid drugs to meet unmet medical needs such as cancer and intractable diseases.This is because nucleic acid drugs have the following advantages.It is possible to target intracellular drug molecules that could not be targeted by conventional drugsDrug discovery research is possible for any gene as long as there is technology to deliver nucleic acids to the expression siteMore specific than low molecular weight compounds and less susceptible to side effects Unlike antibody drugs, nucleic acid drugs can be manufactured by chemical synthesis at a relatively low cost.

Total Funding Amount:

1.2B JPY

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Tokyo, Tokyo, Japan

Founded Date:

2015-01-15

Founders:

Junichi Yano

Number of Employees:

11-50

Last Funding Date:

2017-06-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai